Conditions: Lymphoma Leukemia Multiple Myeloma
Keywords: HDAC inhibitor Oral LBH589 Lymphoma Leukemia Multiple myeloma
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 175
Healthy volunteers: no

Brief summary:
This study evaluated safety, tolerability, pharmacokinetics and preliminary anti-leukemic or anti-tumor activity of LBH589B in adult patients with advanced hematological malignancies

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None arm 4: Panobinostat was administered orally, once-a-day, on Monday-Wednesday-Friday (MWF), every other week, as part of a 28-day treatment cycle. Group Y is a sub-arm, based on disease indication.

Interventions: intervention 1: LBH589
Intervention descriptions: intervention 1: None

Protocol document: